Prkn Antibody

What is PRKN and why is it significant in neurodegenerative research?

PRKN (Parkin RBR E3 ubiquitin-protein ligase) is a 465-amino acid protein with a molecular weight of approximately 52 kDa, encoded by the PRKN gene in humans . As a member of the RBR family, Parkin subfamily, it plays a critical role in mitochondrial quality control through the process of mitophagy .

The protein's significance in research stems from its established role in Parkinson's disease (PD) pathogenesis. Mutations in the PRKN gene are the most frequent cause of autosomal recessive early-onset PD . Furthermore, even heterozygous PRKN mutation carriers may have an increased risk for developing clinical symptoms of PD .

The PINK1-PRKN pathway orchestrates the selective removal of dysfunctional mitochondria, which is critical for cellular health. Impairments in this pathway have been linked not only to PD but also to aging and other neurodegenerative conditions .

How do researchers validate the specificity of PRKN antibodies?

Validation of PRKN antibody specificity involves multiple rigorous approaches:

• Knockout cell line validation: Testing antibodies against PRKN knockout cell lines to confirm absence of signal .

• Cross-reactivity assessment: Evaluating potential cross-reactivity with similar proteins or epitopes. For instance, due to sequence similarity between phosphorylated epitopes around serine 65 in both ubiquitin and PRKN, antibodies are tested against both phosphorylated and non-phosphorylated PRKN protein .

• Multiple application testing: Validating antibodies across different applications including Western blot, immunocytochemistry, and ELISA to ensure consistent detection .

• Comparison with known positive controls: Using established positive controls to benchmark antibody performance .

• Assessment of signal in stress conditions: Comparing signal detection between normal conditions and those that activate the PINK1-PRKN pathway, such as treatment with CCCP (carbonyl cyanide 3-chlorophenylhydrazone) .

For example, recent research on phospho-ubiquitin antibodies demonstrated that their specificity was confirmed by comparing signals between wild-type and PINK1 knockout cells under both baseline and stressed conditions .

What are the primary applications for PRKN antibodies in laboratory research?

PRKN antibodies serve multiple critical applications in neuroscience and cell biology research:

• Western blotting: For detecting and quantifying PRKN protein levels in cell and tissue lysates, with applications across human, mouse, and rat samples .

• Immunocytochemistry/Immunofluorescence: For visualizing subcellular localization of PRKN, particularly important for studying mitochondrial recruitment following damage .

• Flow cytometry: For quantitative assessment of PRKN expression in cell populations .

• Immunohistochemistry: For examining PRKN distribution in tissue sections, particularly valuable in brain tissue studies .

• ELISA (Enzyme-Linked Immunosorbent Assay): For quantitative measurement of PRKN levels in biological samples, including the development of sandwich ELISA methods for increased sensitivity .

• Immunoprecipitation: For isolating PRKN and its binding partners to study protein-protein interactions .

The specific application determines the optimal antibody clone, as different antibodies may perform better in particular applications based on epitope accessibility and antibody characteristics .

How can researchers develop and optimize sensitive methods for measuring PRKN protein levels?

Development of sensitive PRKN detection methods is crucial given its relatively low physiological expression. Current optimization approaches include:

• Antibody pair assessment for sandwich ELISA: Systematically evaluating different PRKN antibody pairs for their ability to sensitively measure PRKN protein levels . This involves:

  • Testing antibodies targeting different epitopes

  • Optimizing antibody concentrations and incubation conditions

  • Validating with samples containing varying PRKN amounts, including negative controls

• Recombinant monoclonal antibody development: Generation of high-affinity rabbit monoclonal antibodies, which has proven successful for phospho-ubiquitin detection in the PINK1-PRKN pathway .

• Signal amplification techniques: Implementation of enhanced detection systems such as the MSD (Meso Scale Discovery) platform that offers superior sensitivity through electrochemiluminescence .

• Sample preparation optimization: Carefully designed lysis protocols that preserve protein modifications, particularly phosphorylation states .

The Michael J. Fox Foundation has supported research specifically focused on developing sensitive methods for PRKN quantification, highlighting its importance for understanding mitophagy's role in PD and for assessing potential therapeutic efficacy .

What considerations should researchers take when selecting antibodies for specific phosphorylation sites on PRKN?

Selection of phospho-specific PRKN antibodies requires careful consideration of several factors:

• Site-specific validation: Antibodies targeting specific phosphorylation sites, such as Ser131 on PRKN, must be validated against synthesized peptides derived from human Parkin around the phosphorylation site .

• Cross-reactivity assessment: Due to sequence similarities between phosphorylated epitopes, rigorous testing must confirm that phospho-PRKN antibodies do not cross-react with other phosphorylated proteins in the same pathway. For instance, testing against p-S65-Ub is crucial for p-S65-PRKN antibodies .

• Signal-to-noise ratio: Evaluation of background signal in negative controls, including knockout samples and non-phosphorylated controls .

• Dynamic range: Assessment of antibody performance across a range of phosphorylation levels, from baseline to maximum induction .

• Application-specific performance: Different antibody clones may exhibit variable performance across applications. For example, an antibody performing well in Western blot might not be optimal for immunohistochemistry .

For phospho-Ser131 PRKN antibodies, researchers have developed specific validation protocols using synthesized peptides spanning positions 101-150 of human Parkin to ensure specificity and sensitivity .

How do heterozygous PRKN mutations affect cellular biomarkers, and how can researchers investigate these effects?

Research into heterozygous PRKN mutation carriers has revealed several associated biomarkers that researchers can investigate:

Experimental design considerations:

• Population-based approach: The Cooperative Health Research in South Tyrol (CHRIS) study identified 164 confirmed heterozygous PRKN mutation carriers compared with 2,582 controls, providing a model for population-level investigation .

• Biomarker panel assessment: Multiple biomarkers should be examined:

  Biomarker	Finding in PRKN Carriers	Statistical Significance
  Akinesia symptoms	Increased reporting	p = 0.006
  Diabetes mellitus	Higher prevalence	p = 0.023
  Resting heart rate	Lower (59.01 vs. 60.6)	p = 0.054
  Neutrophil-to-lymphocyte ratio	Higher (4.91 vs. 4.71)	p = 0.025
  Serum albumin	Lower (4.45 vs. 4.49)	p = 0.008
  Sodium levels	Lower (140.22 vs. 140.44)	p = 0.047

• Screening questionnaire methodology: Utilizing PD screening questionnaires with specific akinesia-related questions like "their feet seem to get stuck to the floor" can help identify subtle motor phenotypes .

• Expanded carrier dataset analysis: When direct sequencing is limited, imputation techniques can be used to expand analysis to potential carriers (299 carriers vs. 7,127 non-carriers in the CHRIS study) .

These biomarkers could potentially serve as an ensemble to identify variant carriers at greater risk of health issues due to their carrier status .

How can researchers use phospho-ubiquitin antibodies to monitor PINK1-PRKN signaling in cells and tissue samples?

Monitoring PINK1-PRKN signaling through phospho-ubiquitin antibodies requires specific methodological approaches:

• Cell-based mitophagy assays:

  • Treatment with mitochondrial uncouplers (e.g., CCCP) to induce PINK1 stabilization

  • Time-course analysis of p-S65-Ub formation

  • Comparison between wild-type and PINK1 or PRKN knockout cells

  • Quantification of p-S65-Ub signals using high-sensitivity detection methods

• Tissue analysis protocol optimization:

  • Rapid tissue preservation to maintain phosphorylation status

  • Optimized extraction buffers containing phosphatase inhibitors

  • Comparison between control and disease-relevant tissues

  • Use of recombinant monoclonal antibodies with high specificity

• Quantitative assessment methodologies:

  • Development of standard curves using recombinant p-S65-Ub

  • Establishment of Limit of Blank (LoB), Limit of Detection (LoD), and Limit of Quantification (LoQ)

  • Calculation of fold-changes between experimental conditions

Recent research demonstrated that newly developed recombinant rabbit monoclonal p-S65-Ub antibodies could detect significant differences in p-S65-Ub levels between DMSO-treated wild-type and CCCP-treated PINK1 knockout cells, even at baseline conditions . The most sensitive antibody clones showed 91- to 144-fold increases in signal when comparing CCCP-treated wild-type cells to CCCP-treated PINK1 knockout cells .

What are the challenges in developing ultrasensitive detection methods for physiological levels of p-S65-Ub?

Developing ultrasensitive detection methods for physiological p-S65-Ub levels presents several methodological challenges:

• Baseline expression challenges: Physiological levels of p-S65-Ub in the absence of exogenous stress are extremely low, making detection difficult without reliable and ultrasensitive methods .

• Cross-reactivity concerns: Due to the sequence similarity between phosphorylated epitopes around serine 65 in both ubiquitin and PRKN, antibodies must be thoroughly validated to ensure specificity .

• Technical limitations in current methods:

  • Standard Western blot approaches may lack sufficient sensitivity

  • Traditional ELISA methods may not achieve required detection limits

  • Signal amplification strategies must balance sensitivity with specificity

• Tissue-specific optimization requirements:

  • Brain tissue analysis requires special considerations due to post-mortem changes

  • Preservation of phosphorylation status is particularly challenging in clinical specimens

  • Background autofluorescence in brain tissue can interfere with detection

• Standardization across laboratories:

  • Establishing consistent protocols for antibody use

  • Developing standardized positive controls

  • Creating reference ranges for physiological p-S65-Ub levels

Recent research has addressed these challenges through development of novel recombinant rabbit monoclonal antibodies that demonstrated high specificity and affinity, allowing detection of subtle differences in p-S65-Ub levels even under baseline conditions .

How can PRKN antibodies be leveraged as diagnostic or prognostic tools in clinical research?

PRKN antibodies have significant potential as diagnostic and prognostic tools in clinical research settings:

• Biomarker development for Parkinson's disease:

  • p-S65-Ub has emerged as a highly specific and quantitative marker of mitochondrial damage with disease relevance

  • Monitoring PINK1-PRKN pathway activation could potentially identify individuals at risk before clinical symptoms manifest

• Surveillance of mitochondrial health in clinical specimens:

  • PRKN antibodies can detect mitochondrial damage in various clinical and pathological specimens

  • This allows for monitoring disease progression and response to interventions

• Stratification of patient populations:

  • Identifying heterozygous PRKN mutation carriers through biomarker panels

  • Using combined biomarkers (akinesia symptoms, diabetes prevalence, heart rate, NLR, albumin and sodium levels) to identify carriers at greater risk

• Therapeutic efficacy assessment:

  • Measuring PRKN levels as a surrogate endpoint for treatments targeting the PINK1-PRKN pathway

  • Using a sensitive PRKN assay to quantify changes in response to therapy

• Longitudinal monitoring protocols:

  • Establishing baseline PRKN levels in at-risk individuals

  • Tracking changes over time to correlate with clinical progression

  • Correlating biomarker changes with clinical outcomes

The development of sensitive and reliable methods to measure PRKN has been identified as essential for understanding how mitophagy contributes to PD and for assessing the efficacy of future therapeutics targeting this pathway .

What experimental approaches can researchers use to study the relationship between PRKN mutations and mitochondrial dynamics?

Studying the relationship between PRKN mutations and mitochondrial dynamics requires multi-faceted experimental approaches:

• Cellular models for comparative analysis:

  • Generating isogenic cell lines with wild-type, heterozygous, and homozygous PRKN mutations

  • Using patient-derived fibroblasts or induced pluripotent stem cells (iPSCs) differentiated into neurons

  • Comparing PRKN knockout models (such as PRKN knockout SH-SY5Y cells) with wild-type counterparts

• Mitochondrial damage induction protocols:

  • Treatment with mitochondrial uncouplers (CCCP) to trigger the PINK1-PRKN pathway

  • Exposure to oxidative stress inducers

  • Application of proteotoxic stress

  • Time-course analysis of mitochondrial recruitment of PRKN and subsequent mitophagy

• Quantitative mitophagy assessment:

  • Monitoring p-S65-Ub formation as a specific marker of PINK1 activation

  • Tracking PRKN translocation to mitochondria

  • Measuring mitochondrial clearance through various assays

  • Correlating findings with mitochondrial functional parameters

• Advanced imaging techniques:

  • Live-cell imaging to track PRKN recruitment to damaged mitochondria

  • Super-resolution microscopy to visualize mitochondrial subdomains

  • Mitochondrial morphology analysis to assess fission/fusion dynamics

• Population-based approaches:

  • Screening for heterozygous PRKN mutations in large cohorts

  • Correlating mutation status with biomarkers of mitochondrial health

  • Longitudinal assessment of mitochondrial function in mutation carriers

These methodological approaches enable researchers to establish the mechanistic links between PRKN mutations, altered mitochondrial quality control, and neurodegeneration, ultimately informing therapeutic strategies targeting this pathway .

How should researchers optimize Western blot protocols for reliable PRKN detection?

Optimizing Western blot protocols for PRKN detection requires attention to several critical parameters:

• Sample preparation considerations:

  • Use lysis buffers containing phosphatase inhibitors when studying phosphorylated forms

  • Process samples rapidly to prevent degradation or dephosphorylation

  • Include protease inhibitors to prevent PRKN degradation during lysis

• Antibody selection and optimization:

  • Choose antibodies validated specifically for Western blot applications

  • Determine optimal antibody concentration through titration experiments

  • For PRKN detection, successful protocols have used ab77924 (PRK8 clone) at 5 μg/ml concentration

• Control implementation:

  • Include knockout controls (such as PRKN knockout SH-SY5Y cell lysate)

  • Use appropriate loading controls (e.g., GAPDH with ab181602 at 1:20000 dilution)

  • Include positive controls with known PRKN expression

• Detection system optimization:

  • Consider fluorescent secondary antibodies for more quantitative results

  • Successful protocols have used IRDye®-conjugated secondary antibodies (800CW and 680RD) at 1:20000 dilution

  • Exposure time optimization based on signal strength

• Detailed protocol example:

  • Proteins separated on SDS-PAGE gels

  • Transferred to PVDF membranes

  • Membranes blocked with 3% milk in TBS-T

  • Primary antibody incubation overnight at 4°C

  • Secondary antibody incubation for 1 hour at room temperature

  • Visualization using appropriate imaging system

Following these methodological guidelines will help ensure consistent and reliable detection of PRKN in Western blot applications, particularly important given the relatively low physiological expression levels of this protein .

What are the methodological considerations for detecting phosphorylated PRKN in tissue samples?

Detection of phosphorylated PRKN in tissue samples presents unique methodological challenges that require specific approaches:

• Tissue preservation protocols:

  • Rapid fixation is critical to maintain phosphorylation status

  • For frozen sections, snap freezing in liquid nitrogen is preferable

  • For FFPE samples, minimize time between tissue collection and fixation

  • Use phosphatase inhibitors in all buffers during tissue processing

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval methods may be necessary

  • Buffer pH optimization is critical for phospho-epitope exposure

  • Careful titration of retrieval conditions to balance signal recovery with tissue morphology preservation

• Antibody selection criteria:

  • Use antibodies specifically validated for tissue applications

  • For phospho-Ser131 PRKN detection, polyclonal antibodies have been successfully used

  • Recommended working dilutions for IHC applications range from 1:100-1:300

• Signal amplification strategies:

  • Consider tyramide signal amplification for low abundance targets

  • Polymer-based detection systems may provide improved sensitivity

  • Minimize background through careful blocking optimization

• Controls and validation approaches:

  • Include tissue from genetic models (e.g., PRKN knockout animals)

  • Use competing peptide controls to confirm specificity

  • Consider lambda phosphatase treatment of serial sections as negative controls

By addressing these methodological considerations, researchers can enhance the reliability and sensitivity of phosphorylated PRKN detection in tissue samples, enabling more accurate assessment of PRKN function in health and disease contexts .

How can researchers address cross-reactivity concerns when using antibodies against both PRKN and phospho-ubiquitin?

Addressing cross-reactivity concerns between PRKN and phospho-ubiquitin antibodies requires systematic validation approaches:

• Direct comparative ELISA assessment:

  • Test antibodies against both phosphorylated and non-phosphorylated forms of PRKN and ubiquitin

  • Quantify relative binding affinities at different antibody concentrations

  • Recent studies demonstrated that at 1 μg/ml concentration, p-S65-Ub antibodies showed 600-6600 fold higher signal for p-S65-Ub compared to p-S65-PRKN

• Western blot validation protocol:

  • Run parallel blots with recombinant p-S65-PRKN and p-S65-Ub proteins

  • Probe with antibodies of interest to assess cross-reactivity

  • Include appropriate positive and negative controls

• Genetic model validation:

  • Test antibody specificity in PINK1 knockout cells/tissues where p-S65-Ub formation is prevented

  • Compare signals between wild-type and knockout samples under basal and stressed conditions

  • Quantify signal-to-background ratios to establish specificity

• Peptide competition assays:

  • Pre-incubate antibodies with excess competing peptides representing the phosphorylated epitopes of PRKN and ubiquitin

  • Assess the degree of signal inhibition to determine epitope specificity

  • This approach can reveal shared epitope recognition

• Application-specific optimization:

  • Recognize that cross-reactivity may vary between applications (Western blot vs. IHC)

  • Establish application-specific validation protocols

  • Consider using multiple antibodies targeting different epitopes for confirmation

These rigorous validation approaches are essential given the sequence similarity between phosphorylated epitopes around serine 65 in both ubiquitin and PRKN, ensuring that experimental findings accurately reflect the intended target protein's biology .

What emerging technologies might enhance the sensitivity and specificity of PRKN detection in research and clinical applications?

Several emerging technologies show promise for enhancing PRKN detection:

• Single-molecule detection platforms:

  • Digital ELISA technologies (e.g., Simoa) capable of single-molecule detection

  • Offering potential attomolar sensitivity for proteins in complex matrices

  • Particularly valuable for detecting physiological levels of p-S65-Ub under basal conditions

• Proximity-based assay advancements:

  • Proximity ligation assays (PLA) to detect PRKN interaction with binding partners

  • Allowing visualization of protein-protein interactions in situ

  • Enhancing sensitivity through signal amplification strategies

• Mass spectrometry-based approaches:

  • Targeted proteomics using selected reaction monitoring (SRM)

  • Parallel reaction monitoring (PRM) for multiplexed detection of PRKN and its modifications

  • Label-free quantification methods for unbiased assessment

• Nanobody and aptamer technologies:

  • Development of nanobodies with enhanced epitope accessibility

  • Aptamer-based detection systems with high affinity and specificity

  • Potentially offering improved tissue penetration and reduced background

• Microfluidic-based detection systems:

  • Lab-on-a-chip approaches for automated sample processing

  • Reduced sample volume requirements

  • Enhanced sensitivity through confined reaction spaces

• Multiplexed imaging technologies:

  • Cyclic immunofluorescence to detect multiple targets in the same sample

  • Mass cytometry imaging for highly multiplexed tissue analysis

  • Spatial transcriptomics combined with protein detection

These technological advancements may provide the ultrasensitive detection capabilities needed to monitor physiological PRKN levels and modifications, potentially transforming both basic research and clinical applications in the field of neurodegeneration .

How might PRKN antibodies contribute to therapeutic development for Parkinson's disease?

PRKN antibodies can significantly advance therapeutic development for Parkinson's disease through multiple research pathways:

• Target engagement assessment:

  • Quantifying PRKN levels and activity to measure response to PRKN-targeted therapies

  • Serving as a pharmacodynamic biomarker in clinical trials

  • Enabling dose-response studies for novel therapeutic candidates

• Patient stratification protocols:

  • Identifying heterozygous PRKN mutation carriers who might benefit from specific interventions

  • Using PRKN-related biomarkers to select appropriate patients for clinical trials

  • Creating more homogeneous study populations to enhance statistical power

• Preclinical model validation:

  • Evaluating PRKN function in cellular and animal models of PD

  • Confirming target modulation before advancing to clinical studies

  • Comparing efficacy across different model systems

• Mechanism of action studies:

  • Elucidating how candidate therapeutics affect the PINK1-PRKN pathway

  • Distinguishing between compounds that enhance PRKN stability versus activity

  • Mapping downstream effects on mitochondrial quality control

• Combinatorial therapy approaches:

  • Assessing synergistic effects when targeting multiple nodes in the mitophagy pathway

  • Developing rational drug combinations based on pathway analysis

  • Monitoring pathway activation in response to combination treatments

The Michael J. Fox Foundation has specifically highlighted that developing sensitive methods for PRKN quantification will be essential for understanding how mitophagy contributes to PD and for assessing the efficacy of future therapeutics targeting this pathway . Such tools would facilitate assessment of PRKN levels in both preclinical models and people with PD, serving as important surrogates for treatments that might become available in the future .